Skip to content

Epidaurus · Treatment Guide · Diagnostic Services

Going abroad for —

Cancer Screening Quality

Cancer detection and screening program quality

The country comparison

Which countries are best for cancer screening quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 United Kingdom GB 5.0/5 Good The United Kingdom maintains four comprehensive national cancer screening programmes (breast, cervical, bowel, lung) aligned with IARC and WHO guidelines, with world-leading outcomes including a 26% reduction in breas... Full report
    The evidence behind this score 5 cited points
    • Four national screening programmes (breast, cervical, bowel, lung) with 9.0 per 1,000 breast cancer detection rate (2024-25), 68.8% cervical coverage (2023-24), and 67.6% bowel programme uptake with 5,320 cancers detected annually
    • State-of-the-art technology widely available: 3D tomosynthesis mammography, AI-enhanced imaging (ProFound AI), low-dose CT lung screening, PET-CT, SPECT-CT, and NHS-Galleri multi-cancer early detection blood test (142,000 participants)
    • 10+ accredited international patient facilities including Cromwell Hospital (140+ countries), HCA Healthcare UK (70+ countries, 6 hospitals), The Royal Marsden Private Care (Outstanding CQC rating), and GenesisCare UK (14 centres)
    • Demonstrated cancer mortality reduction: 26% reduction in breast cancer mortality, 7% reduction in colorectal cancer incidence, stage 1 lung cancer 5-year survival over 90% vs. 4% for stage 4 diagnoses
    • Systematic quality assurance with published outcome data: NHS Screening Quality Assurance Service conducts regular on-site visits, annual KPI reports published, NHS-Galleri trial published in peer-reviewed journals including Nature Medicine

    Read the full United Kingdom report →

  2. 2 Spain ES 4.5/5 Good Spain demonstrates strong cancer screening quality with three population-based national programs (breast, colorectal, cervical) aligned with international guidelines and excellent outcomes including breast cancer 5-ye... Full report
    The evidence behind this score 4 cited points
    • Spain operates three national screening programs (breast, colorectal, cervical) meeting EU participation targets; breast program achieves 70%+ participation, meeting EU benchmarks; colorectal program uses FIT with 20.6 per 1,000 detection rate for high-risk adenomas.
    • Córdoba Breast Tomosynthesis Screening Trial demonstrates Spain's research leadership with 3D mammography achieving 86.72% sensitivity versus 77.24% for standard 2D, and 49% reduction in interval cancer rates.
    • Multiple internationally accredited facilities (Teknon, CUN, Quirónsalud, Jiménez Díaz Foundation, Dexeus, Ruber Internacional) offer integrated oncology screening packages with English support, multidisciplinary tumor boards, and seamless care coordination.
    • Spain demonstrates exceptional cancer outcomes: breast cancer 5-year survival 85.2% (among highest in major European economies), overall cancer mortality among EU's lowest, and 19% reduction in potential years of life lost since 2012.

    Read the full Spain report →

  3. 3 South Korea KR 4.5/5 Good South Korea demonstrates exceptional cancer screening quality through its comprehensive six-cancer National Cancer Screening Program with world-leading mortality-to-incidence ratios (stomach cancer 0.24 vs OECD 0.45, ... Full report
    The evidence behind this score 5 cited points
    • National Cancer Screening Program covers six major cancers (stomach, liver, cervical, breast, colorectal, lung) with guidelines aligned to international standards and screening rates increasing dramatically (stomach 39.2% to 77.5%, colorectal 19.9% to 70.7%, breast 33.2% to 72.7%)
    • Mortality-to-incidence ratios substantially below OECD averages: stomach cancer 0.24 (OECD 0.45), breast cancer 0.08 (OECD 0.16), cervical cancer 0.26 (OECD 0.34), colorectal cancer 0.27 (OECD 0.35)
    • Multiple JCI-accredited major hospitals (Asan Medical Center ranked 25th globally, Samsung Medical Center, Seoul National University Hospital, Korea University Anam Hospital) with screening detection rates improving from 1.5 to 3.1 per 1,000 (2009-2020)
    • Mandatory Quality Assurance Program achieving unsatisfactory Pap test rate below 0.2% and cytology-histology discrepancy under 0.6% across over 10 million annual examinations
    • Over 55,000 medical tourists annually access screening packages with multilingual support (10 languages), free airport pickup, and comprehensive 4-6 hour packages at 40-60% lower cost than Western equivalent services

    Read the full South Korea report →

  4. 4 Singapore SG 4.5/5 Good Singapore delivers excellent cancer screening infrastructure with systematic national programs covering four major cancers (breast, cervical, colorectal, lung) aligned to IARC guidelines, state-of-the-art imaging tech... Full report
    The evidence behind this score 6 cited points
    • Four major cancers covered under Healthier SG Screening and 2026 STRC guidelines aligned to IARC standards (breast, cervical, colorectal, lung)
    • State-of-the-art screening technology including full-field digital mammography with CAD, 3D tomosynthesis, contrast-enhanced spectral mammography, AI-assisted reading (FxMAMMO validated at NUH), and LDCT available at multiple private sites
    • Breast cancer five-year survival rate 84.2% (2019-2023) with 56.3% of cases diagnosed at Stage I; overall five-year cancer survival 61.4% (improved from 22.6% in 1978-1982)
    • Five JCI-accredited hospitals specifically identified for international patient cancer screening (Mount Elizabeth Orchard, Mount Elizabeth Novena, Gleneagles, Parkway East, Raffles) with dedicated Patient Assistance Centres and multilingual support
    • Competitive pricing for medical tourists: comprehensive cancer screening package S$558 (~US$410), MCED liquid biopsy S$1,999 (~US$1,470), substantially lower than US/UK/Australia
    • SOLSTICE lung cancer screening study detected 100% of cancers at Stage 1A (1.9% detection rate), addressing Asian non-smoker population with 70%+ five-year survival rates

    Read the full Singapore report →

  5. 5 Germany DE 4.5/5 Good Germany operates world-class cancer screening infrastructure across six major cancers with international guideline adherence and state-of-the-art technology, including the newly launched AI-mandatory low-dose CT lung ... Full report
    The evidence behind this score 4 cited points
    • Breast cancer screening: landmark 2025 BfS study on 10 million women demonstrates 20–30% mortality reduction; 94–95 certified screening units with mandatory double-reading and full-field digital mammography
    • Technology: low-dose CT lung cancer screening with mandatory AI-assisted nodule detection launched April 1, 2026; colorectal colonoscopy registry tracks adenoma detection rates and complications at per-physician level
    • Facilities: 138+ ISO-certified hospitals offering comprehensive multi-cancer prevention packages to medical tourists; 2,159 DKG-certified cancer centers ensure multidisciplinary management for positive findings
    • Access limitation: statutory programs restricted to German health insurance holders; medical tourists must use private packages (€9,943–€10,951 with 48-hour appointment availability and English-speaking coordinators) rather than direct access to proven national programs

    Read the full Germany report →

  6. 6 Malaysia MY 4.0/5 Good Malaysia offers good cancer screening services specifically for medical tourists, with three major cancers covered by national programs (cervical, breast, colorectal), state-of-the-art technology including 3D mammogra... Full report
    The evidence behind this score 5 cited points
    • Three national cancer screening programs with international guideline adherence: cervical cancer screening with HPV self-sampling (2023 update), breast cancer biennial mammography (age 50-74 via eMAMOGRAM 2.0), and colorectal cancer iFOBT screening (age 50-74); no national lung or prostate programs exist.
    • State-of-the-art screening technology deployed at leading private hospitals including 3D mammography/tomosynthesis, low-dose CT scanners, SPOT-MAS 10-cancer blood test (99.7% specificity, K-DETEK Trial validated), AI-enhanced imaging (Qure.AI for lung cancer, ENDO-AID CADe for colorectal), and PET-CT systems.
    • At least 5-9 clearly identified JCI/ACHS-accredited facilities offering cancer screening for international patients: Sunway Medical Centre (triple-accredited JCI+ACHS+MSQH, ESMO Designated Centre), Mahkota Medical Centre (first in Malaysia with JCI Breast Cancer Clinical Care Programme Certification), Island Hospital Penang, Pantai Hospital, Prince Court Medical Centre, and others; MHTC reports over 90 registered private healthcare facilities participating in medical tourism.
    • Comprehensive cancer screening packages available at RM1,499-RM3,600 (~USD330-USD800), representing 40-60% cost savings versus UK/US/Australia; international patients can complete multi-cancer screening within one to two days with dedicated multilingual coordinators and international patient services.
    • Established follow-up protocols and care coordination at JCI-accredited hospitals with structured multidisciplinary oncology teams; Mahkota's JCI CCPC certification ensures documented screening-to-treatment pathways; Subang Jaya reports 88% five-year breast cancer survival with Stage I achieving 100% survival.

    Read the full Malaysia report →

  7. 7 Colombia CO 4.0/5 Good Colombia has established national screening programs for breast, cervical, and colorectal cancers that align with international guidelines (IARC/USPSTF), supported by Law 2360/2024 and Circular 010/2024 quality mandat... Full report
    The evidence behind this score 4 cited points
    • National breast cancer guidelines recommend biennial mammography for women 50–69 and annual clinical exam from age 40, aligned with IARC/USPSTF standards and reinforced by Law 2360/2024 and Circular 010/2024 quality mandates
    • Digital 3D mammography/tomosynthesis available at multiple private facilities including Colsanitas (Bogotá), CediMed (Medellín), Clínica FOSCAL (Bucaramanga), and DIMA (Antioquia); Fundación Valle del Lili operates proton therapy and South America's most advanced cancer center
    • Six JCI-accredited hospitals offer structured international patient services; Hospital Pablo Tobón Uribe's executive health packages including cancer screening cost $380–$1,110 USD with 4-day result turnaround
    • Cervical cancer mortality declined from 14/100,000 (1987) to 7.1/100,000 (2018) partly attributable to Pap smear screening programs; Instituto Nacional de Cancerología holds ICONTEC health accreditation and four IARC-recognized cancer registries provide epidemiological surveillance

    Read the full Colombia report →

  8. 8 Israel IL 4.0/5 Good Israel operates comprehensive national screening programs for 4+ major cancers (breast, colorectal, cervical, skin, and lung pilot) with strong adherence to international guidelines and demonstrated mortality reductio... Full report
    The evidence behind this score 5 cited points
    • Israel has organized national screening programs for breast (70-72% participation), colorectal (FIT, declining 2-3% annually for 15 years), cervical (Pap, 25-54), and skin cancer (91.9% early-stage diagnosis rate in 2020, ranking last—best—in melanoma mortality among 30 highest-incidence countries)
    • Five JCI-accredited major medical centers serve international patients: Sheba (ranked 7th globally, MD Anderson partnership), Ichilov (JCI, Newsweek top 10), Rambam (97.5% JCI score), Hadassah (Newsweek top 250 oncology), and Assuta; Hadassah features world-first integrated 7-Tesla PET/MRI for cancer screening
    • Colorectal cancer early-stage diagnosis doubled from 19.9% (2000) to 39.6% (2021) with FIT/colonoscopy screening reducing CRC mortality by 70-77%; systematic follow-up colonoscopy protocols ensure compliance across all four HMOs
    • Comprehensive quality assurance through National Quality Indicators Program and mandatory Israel National Cancer Registry (since 1982) enabling outcome tracking and continuous improvement; skin cancer annual campaigns and breast/colorectal screening inclusion in quality metrics drove substantial participation gains
    • Medical tourism infrastructure well-developed with 40-60% cost advantage vs US, dedicated international coordinators, multilingual support, oncologist consultations from ~$500, and comprehensive screening packages (Assuta Platinum Check-up ~$5,200); seamless care coordination via MD Anderson and Roche partnerships

    Read the full Israel report →

  9. 9 Japan JP 4.0/5 Good Japan operates comprehensive national screening programs for five major cancers with modern technology including AI-assisted colonoscopy and PET-CT available at major medical centers. Multiple JCI-accredited hospitals... Full report
    The evidence behind this score 5 cited points
    • Five national cancer screening programs (gastric, colorectal, lung, breast, cervical) with endoscopic gastric screening introduced nationwide in 2016
    • State-of-the-art screening technology including AI-assisted colonoscopy covered by national insurance since February 2024, low-dose CT, 3D mammography, and deep learning-enhanced diagnostic systems
    • Multiple JCI-accredited facilities with international services: St. Luke's International Hospital (JCI-accredited, MediLocus medical tourism clinic), Cancer Institute Hospital JFCR (Japan's largest dedicated cancer hospital with international service section), and Saitama Medical University IMC (JCI-accredited since 2015)
    • Endoscopic screening reduces gastric cancer mortality by 61% in prospective population-based evidence; world-leading outcome with 80% early-stage detection rate
    • Persistent accessibility barriers: 47.4% breast cancer screening participation (vs. OECD 70%), coordinating agents required for National Cancer Center Japan access, majority of Ningen Dock facilities operate in Japanese only with 1-month+ delays for English results

    Read the full Japan report →

  10. 10 Turkey TR 4.0/5 Good Turkey achieves a Good rating for cancer screening services available to medical tourists. The country offers national screening programs for three major cancers (breast, cervical, colorectal) with international guide... Full report
    The evidence behind this score 5 cited points
    • More than 50 JCI-accredited hospitals offering state-of-the-art screening technology including 3D mammography, low-dose CT for lung cancer, and computer-aided detection systems
    • National screening programs for breast (ages 40-69, biennial), cervical (ages 30-65, HPV-DNA every 5 years), and colorectal cancer (ages 50-70, FOBT every 2 years) with 202 KETEM centers
    • Comprehensive cancer screening packages designed for medical tourists costing €300-€1,000 (50% below Western countries) with results available within 24-48 hours
    • Bahçeşehir Mammography Screening Project demonstrated 70.2% early-stage detection (stages 0-I) compared to 31.5% in non-screened populations, with cost-effectiveness of $2,423 per life year saved
    • Excellent medical tourism infrastructure with multilingual staff, dedicated international patient coordinators, and established protocols for abnormal result follow-up and treatment referral

    Read the full Turkey report →

  11. 11 United Arab Emirates AE 4.0/5 Good The UAE operates three parallel regional cancer screening programs covering breast, colorectal, and cervical cancers with national MoHAP guidelines, and medical tourists access state-of-the-art technology (3D mammogra... Full report
    The evidence behind this score 5 cited points
    • Three parallel regional screening programs (Dubai's Basmah, Abu Dhabi's IFHAS, Northern Emirates' ITMENAN) covering breast, colorectal, and cervical cancers with MoHAP national guidelines updated in 2023
    • Cleveland Clinic Abu Dhabi, American Hospital Dubai (NAPBC-accredited), King's College Hospital Dubai, and Mediclinic operate 3D mammography, AI-assisted colonoscopy (6 units, 2,000+ patients in 2024), and liquid-biopsy colorectal testing
    • Medical tourists can book same-week comprehensive multi-cancer screening packages (AED 1,800–8,200 / USD 490–2,230) at 200+ JCI-accredited facilities with dedicated international patient coordinators and multilingual support
    • Breast cancer five-year survival approximately 89%; IFHAS programme achieved 80%+ early-stage cancer detection in 2024 with 34,000+ women screened
    • Key gaps: No unified national call-and-recall system; advanced screening technology concentrated in Dubai and Abu Dhabi; national population screening uptake only ~25%; absence of published standardized outcome metrics like UK NHS or Korea programmes

    Read the full United Arab Emirates report →

  12. 12 United States US 3.5/5 Moderate The United States maintains world-class cancer screening programs with state-of-the-art technology, comprehensive USPSTF guidelines covering five major cancers, and mandatory quality accreditation systems that produce... Full report
    The evidence behind this score 5 cited points
    • Comprehensive USPSTF screening programs for breast (age 40+, biennial), colorectal (45–75), cervical, lung, and prostate cancers with evidence-based international guideline adherence.
    • State-of-the-art screening technology widely available: 3D mammography detecting 41% more invasive cancers, low-dose CT lung screening at major medical centers, 88.3% first-attempt pass rate for mandatory MQSA accreditation.
    • High screening uptake (80% mammography, 78% cervical, 65% colorectal in 2023) and documented cancer mortality reduction: 4 million deaths averted since 1991.
    • Prohibitive costs for medical tourists: colonoscopy $1,000–$3,000 (vs. $200–$500 elsewhere), mammogram $300 hospital price; report states 'extraordinarily high costs make it an unattractive destination' for international patients and notes Americans travel abroad for lower-cost screening.
    • Limited medical tourism infrastructure: major cancer centers (City of Hope, Roswell Park, Mayo Clinic) offer international patient services primarily for cancer treatment, not routine screening; few dedicated international screening programs compared to developed medical tourism destinations.

    Read the full United States report →

  13. 13 Brazil BR 3.5/5 Moderate Brazil has national screening programs for 2-3 major cancers (breast, cervical, skin) with modern technology available at elite private facilities, including AI-enhanced imaging and low-dose CT. Multiple JCI-accredite... Full report
    The evidence behind this score 4 cited points
    • National programs exist for breast cancer (expanded to ages 40-74 in Sept 2025), cervical cancer (transitioning to HPV testing per IARC/WHO standards in Feb 2025), and skin cancer (annual national campaign since 1999), but no organized programs for colorectal, lung, or prostate screening
    • State-of-the-art screening technology available at elite private hospitals: digital mammography (69.58% of market), 3D tomosynthesis, AI-enhanced imaging (CureMetrix cmAngio cleared March 2024), and AI-powered low-dose CT with 92.5% sensitivity at Hospital Israelita Albert Einstein
    • Approximately 25 Brazilian hospitals are JCI-accredited, with 3 major facilities (Albert Einstein, Sírio-Libanês, Moinhos de Vento) offering dedicated International Patient Centers with multilingual support and integrated oncology pathways
    • Critical failure on effectiveness: breast cancer mortality rose from 10.5 to 11.8 per 100,000 (2000–2021); public system coverage reaches only 30.6% for breast cancer and 35.6% for cervical cancer vs WHO 70% threshold; cervical cancer incidence of 15.38/100,000 remains nearly 4× above WHO elimination target

    Read the full Brazil report →

  14. 14 Hungary HU 3.5/5 Moderate Hungary has organized national screening programs for three major cancers with modern technology—notably AI-assisted breast screening at five sites and advancing lung cancer LDCT—plus multiple JCI/ISO-accredited priva... Full report
    The evidence behind this score 4 cited points
    • Hungary operates organized national screening programs for breast (43 digital stations, AI double-reading at 5 sites with 35,000+ annual screenings), cervical (HPV reform in progress), and colorectal (though at 9% participation, the lowest in the EU); lung LDCT pilot expanding to 18 centers.
    • Private sector strength: 6+ JCI/ISO-accredited facilities (Liv Duna JCI, Medicover ISO 9001, Buda Health Center 5 locations, FirstMed, Zenon Clinic, RMC Clinics) explicitly serve international patients in English at 50%+ cost advantage (colonoscopy ~USD 565 vs USD 1,150+ in Austria).
    • Outcome failure: Hungary holds the EU's highest cancer mortality rate at ~328 per 100,000 (33% above EU average); lung cancer incidence highest in EU; breast cancer participation declined 10.6 percentage points (2011–2021) and stands at 42% vs EU average 53.4%; colorectal participation at 9% is uniquely low.
    • Technology strengths offset by participation/outcome gaps: AI-assisted breast reading (22 cancers detected by AI above radiologist detection), HUNCHEST II lung LDCT achieved 80% operability, external quality assurance in national programs—but population-level screening impact is the EU's worst.

    Read the full Hungary report →

  15. 15 India IN 3.5/5 Moderate India offers world-class cancer screening technology at over 50 JCI-accredited facilities with exceptional cost advantages for medical tourists, but this excellence is compromised by inadequate quality assurance syste... Full report
    The evidence behind this score 7 cited points
    • Over 50 JCI-accredited hospitals exceeding facility thresholds for medical tourism services
    • State-of-the-art screening technology available including 3D digital mammography with tomosynthesis and low-dose CT, but geographically concentrated in tier 1/2 cities
    • National programs cover only 3 major cancers (breast, cervical, oral) with extremely low population participation (1.9% for cervical, 0.9% for breast cancer screening)
    • Quality assurance mechanisms explicitly described as 'inadequate' with inconsistent supervision across states and districts
    • Follow-up compliance critically low at 30.1% for screen-positive individuals despite dedicated navigation and free services, indicating coordination weaknesses
    • Exceptional pricing of $75-375 for screening packages represents 60-90% savings compared to Western countries
    • No national programs for colorectal or lung cancer screening despite rising incidence, limiting comprehensive screening access

    Read the full India report →

  16. 16 Mexico MX 3.5/5 Moderate Mexico has binding screening guidelines for three major cancers (cervical, breast, prostate) and advanced technology at major private hospitals, but public-sector implementation is weak with mammography coverage at on... Full report
    The evidence behind this score 4 cited points
    • National screening programs exist via legally binding Normas Oficiales Mexicanas for cervical (NOM-014), breast (NOM-041), and prostate cancer, meeting the 2-3 major cancers threshold
    • Digital mammography dominates 89.62% of Mexico's equipment market; 3D tomosynthesis deployed at major hospitals; ABC Medical Center operates liquid biopsy and genomic testing capabilities
    • At least four hospital systems (Hospital Galenia, Christus Muguerza network, ABC Medical Center, Hospital Real San José) offer JCI-accredited international patient cancer screening with English-language support
    • Critical implementation gaps: public mammography coverage only 20.14% vs WHO benchmark of 70%; cervical cancer screening shows 49.9-51% of CIN2/3 cases lost to follow-up; no population-based colorectal screening program despite it being the leading cancer killer; overall cancer mortality up 126% over 30 years

    Read the full Mexico report →

  17. 17 Thailand TH 3.5/5 Moderate Thailand demonstrates strong infrastructure and technology for cancer screening with 62 JCI-accredited facilities offering state-of-the-art diagnostic equipment, but effectiveness of national screening programs is mix... Full report
    The evidence behind this score 4 cited points
    • National Cervical Cancer Screening Program launched 2005 covering 76 provinces; cervical cancer incidence declined from 23.4 per 100,000 women in 1990 to 11.7 per 100,000 in 2014
    • Thailand operates 62 Joint Commission International (JCI) accredited medical facilities as of July 2024, with Bumrungrad recognized consecutively as World's Best Hospital 2021-2024 and offering state-of-the-art 3D mammography and dedicated MRI scanning
    • Colorectal cancer program between 2018-2021 achieved only 30.6% follow-up colonoscopy rate on positive FIT tests, with polyp detection rate of 21.0% and cancer detection rate of 3.1%, significantly below international standards; only 3% of eligible population received FIT screening in 2022
    • Breast cancer screening remains opportunistic rather than population-based, with cancer centers providing mammography screening only upon patient request for women over 45 years

    Read the full Thailand report →

  18. 18 Poland PL 3.0/5 Moderate Poland operates four national cancer screening programs with modern technology and a growing institutional framework, but achieves only moderate overall quality for international patients. Public program participation... Full report
    The evidence behind this score 4 cited points
    • Poland has four national cancer screening programs (breast, cervical, colorectal, lung LDCT) governed by the National Oncology Strategy 2020–2030, but participation rates are critically low: breast 32–37% vs. 70% recommended, cervical organized program 10.9%, colorectal 17%
    • Poland has the lowest mammography unit density in the EU (1.0 units per 100,000 inhabitants), indicating infrastructure constraints despite modern digital mammography standards and LDCT with rigorous 16+ row spiral CT specifications
    • Breast cancer five-year net survival is 77.33% (2000–2019), approximately six percentage points below the EU average, while cervical cancer incidence and mortality remain higher than Western European countries despite nearly two decades of organized screening
    • Medical tourists cannot access national programs (residents only) but can access 3–5 private providers including JCI-accredited LuxMed and Medicover, offering comprehensive multi-cancer packages at 50–80% cost savings vs. United States, though coordination challenges and long diagnostic waiting times are documented systemic problems

    Read the full Poland report →

  19. 19 Jordan JO 3.0/5 Moderate Jordan offers basic national screening infrastructure centered on the breast cancer program (JBCP), with excellent facilities like JCI-accredited KHCC and modern imaging technology at top Amman centers. However, the a... Full report
    The evidence behind this score 4 cited points
    • Only one organized national screening program (Jordan Breast Cancer Program for breast cancer); no programs for colorectal, cervical, lung, or prostate cancers despite colorectal being the leading male cancer
    • 4-5 accredited facilities for medical tourists: KHCC (JCI-accredited disease-specific cancer center), Specialty Hospital Women's Imaging Center (3D tomosynthesis, HCAC-accredited), Abdali Hospital (JCI-accredited breast center), Al Khalidi Medical Center
    • Critically low screening uptake (7-9% mammography nationally) with 50-70% of breast cancers detected at advanced stages (stages III-IV) compared to 6% with metastatic disease at diagnosis in US/UK, indicating systemic implementation failure
    • Quality disparities: 33% of Jordan's ~82 mammography units exceed ACR radiation dose limits; non-accredited facilities deliver 69% higher doses than accredited centers; only ~30% of units are HCAC-accredited

    Read the full Jordan report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for cancer screening quality, top to bottom. How we score →

  1. 5/5 Excellent

    - Comprehensive national screening programs for 4+ major cancers with international guideline adherence - State-of-the-art screening technology widely available (3D mammography, low-dose CT, etc.) - 10+ accredited facilities offering medical tourism screening packages - Systematic quality assurance with published outcome data showing excellent performance - Seamless coordination between screening and treatment services for international patients - Competitive pricing with clear value proposition for medical tourists - Demonstrated cancer mortality reduction through screening programs

  2. 4/5 Good

    - National screening programs for 2-3 major cancers with good guideline adherence - Modern screening technology available at major medical centers - 5-9 accredited facilities with international patient screening services - Quality monitoring systems in place with good outcome data - Established protocols for abnormal result follow-up and treatment referral - Reasonable pricing competitive with developed countries - Evidence of screening program effectiveness

  3. 3/5 Moderate

    - Basic national screening programs for 1-2 major cancers - Standard screening technology available but may not be cutting-edge - 2-4 facilities offering structured screening services for medical tourists - Some quality oversight but limited outcome reporting - Basic follow-up protocols but coordination challenges may exist - Moderate cost savings compared to developed countries - Limited evidence of population-level screening impact

  4. 2/5 Poor

    - Minimal or poorly implemented national screening programs - Outdated screening technology or limited availability - 1-2 facilities with basic screening capabilities for international patients - Limited quality assurance or outcome monitoring - Inconsistent follow-up protocols and coordination gaps - Unclear value proposition for medical tourists - Little evidence of screening program effectiveness

  5. 1/5 Very Poor / Unavailable

    - No systematic cancer screening programs - Inadequate or obsolete screening technology - No facilities specifically serving medical tourists for screening - Absence of quality monitoring or outcome data - Poor coordination between screening and treatment services - No cost advantage or unclear pricing - No evidence of screening impact on cancer outcomes

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source waocp.com/journal/index.php/apjcc/article/view/364 Cited in Cancer Screening Quality in India
  2. Untitled source accreditationsupport.acr.org/support/solutions/articles/11000063274-complete-accreditation-information-mammography-revised-4-9-25- Cited in Cancer Screening Quality in United States
  3. Untitled source ascopubs.org/doi/10.1200/GO-25-00458 Cited in Cancer Screening Quality in India
  4. Untitled source bangkokhealthservice.com/health-check-up-in-thailand/cancer-screening-packages-in-bangkok Cited in Cancer Screening Quality in Thailand
  5. Untitled source bangkokhealthservice.com/medical-check-up-bangkok-price-prices-packages-and-what-you-need-to-know Cited in Cancer Screening Quality in Thailand
  6. Untitled source bangkokhealthservice.com/medical-package Cited in Cancer Screening Quality in Thailand
  7. Untitled source bangkokhealthservice.com/medical-package/cancer-screening-basic-advanced-early-detection-2-nights-packages Cited in Cancer Screening Quality in Thailand
  8. Untitled source beamradiology.com/services/ct-lung-screening-program Cited in Cancer Screening Quality in United States
  9. Untitled source bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14859-6 Cited in Cancer Screening Quality in India
  10. Untitled source bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-23847-1 Cited in Cancer Screening Quality in Turkey
  11. Untitled source bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-021-01558-0 Cited in Cancer Screening Quality in United States
  12. Untitled source cancerrounds.com/costs/cancer-treatment-cost-india Cited in Cancer Screening Quality in India
  13. Untitled source cancerrounds.com/costs/genetic-testing-cost-for-cancer-india Cited in Cancer Screening Quality in India
  14. Untitled source cancerrounds.com/treatments/cancer-screening-thailand Cited in Cancer Screening Quality in Thailand
  15. Untitled source chestsurgeryindia.com/blog/cost-of-lung-cancer-treatment-in-india Cited in Cancer Screening Quality in India
  16. Untitled source clinicsoncall.com/en/clinics/country-south-korea/oncology Cited in Cancer Screening Quality in South Korea
  17. Untitled source ctbreastimaging.org/services/3d-mammography Cited in Cancer Screening Quality in Thailand, Cancer Screening Quality in United States
  18. Untitled source doinasia.com/thailand-medical-tourism-strategies Cited in Cancer Screening Quality in Thailand
  19. Untitled source ecancer.org/en/journal/article/1742-cancer-screening-uptake-by-women-from-indias-largest-state-uttar-pradesh-district-wise-analysis-from-the-fifth-round-of-national-family-health-survey-2019-2021 Cited in Cancer Screening Quality in India
  20. Untitled source en.wikipedia.org/wiki/Joint_Commission Cited in Cancer Screening Quality in United States
  21. Untitled source en.wikipedia.org/wiki/Medical_tourism_in_South_Korea Cited in Cancer Screening Quality in South Korea
  22. Untitled source en.wikipedia.org/wiki/National_Cancer_Control_Programme Cited in Cancer Screening Quality in India
  23. Untitled source eng.nhso.go.th/view/1/DescriptionNews/Cancer-screening-tests-provided-to-Thais/415/EN-US Cited in Cancer Screening Quality in Thailand
  24. Untitled source eng.nhso.go.th/view/1/DescriptionNews/Mammography-and-ultrasound-breast-cancer-screening-to-be-accessible-for-Thai-women-with-high-risk/592/EN-US Cited in Cancer Screening Quality in Thailand

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Diagnostic Services

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Cancer Screening Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison